# US 2026/0091081 A1 · A formulation of a conjugate of a tubulysin analog to a cell-binding molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091081 A1
- Document ID: US20260091081A1
- Status: Published application
- Kind: A1
- Application number: 19/352,876
- Filed: 2025-10-08
- Published: 2026-04-02
- Earliest claimed: 2019-06-24
- Assignees: Hangzhou Dac Biotech Co., Ltd.
- Applicants: Hangzhou Dac Biotech Co., Ltd
- Inventors: Robert ZHAO; Qingliang YANG; Yuanyuan HUANG; Shun GAI; Hangbo YE; Linyao ZHAO; Huihui GUO; Lu BAI; Wenjun LI; Junxiang JIA; Zhixiang GUO; Jun ZHENG; Xiaoxiao CHEN; Xiangfei KONG; Chen LIN; Yong DU; Yu ZHANG; Lei ZHOU; Xiuzhen ZHANG; Xiuhong ZHENG; Binbin CHEN; Yanlei YANG; Meng DAI; Yifang XU; Zhongliang FAN; Xiaomai ZHOU; Xingyan JIANG; Miaomiao CHEN; Lingli ZHANG; Yanhua LI
- Web page: https://patentgrep.com/patent/US20260091081A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

## Claims

### Claim 1

A conjugate having a structure of Formula (II):
or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or an isotope, optical isomer, racemate, diastereomer or enantiomer thereof;
wherein T is an antibody;
L is a releasable linker having a formula: -Ww-(Aa)r-Vv-; wherein —W— is
wherein R20 is —C1˜C9 alkylene-, —C1˜C7 carbocyclo-, —O—(C1-C8 alkyl)-, -arylene-, —C1-C9 alkylene-arylene-, -arylene, —C1-C9 alkylene-(C1-C8 carbocyclo)-, —(C1-C7 carbocyclo)—C1-C9 alkylene-, —C1-C8 heterocyclo-, —C1-C10 alkylene-(C1-C8 heterocyclo)-, —(C1-C8 heterocyclo)—C1-C9 alkylene-, —(CH2CH2O)k—, —(CH(CH2)CH2O)k—, and —(CH2CH2O)k—CH2—; k is an integer ranging from 1-20; w is 1, r and v are 0;
n is 1-20;
m is 1-10;
Y is N;
R1 is a linear or branched C1-C8 alkyl, or alkyl alcohol; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl, alkyl ether, alkyl carboxylate, alkyl amine, alkyl ester, or alkyl amide; or C3-C8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, or heteroalkylcycloalkyl;
R2 is absent, a linear or branched C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl, alkyl ether, alkyl carboxylate, alkyl amine, alkyl ester, or alkyl amide; or
C3-C8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, or heteroalkylcycloalkyl;
R3, R4, R5, R6, and R8 are independently H or a linear or branched C1-C4 alkyl;
R7 is R14, —R14C(═O)X1R15 or —R14X1R15; X1 is selected from O, S, S—S, NH, or NR14;
R9 is H, —O— or —OR20, wherein R20 is H; C1-C8 linear or branched alkyl, heteroalkyl, or acyl (—C(O)R17); C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; carbonate (—C(O)OR17), carbamate (—C(O)NR17R18); or C1-C8 carboxylate, ester, ether, or amide; or 1-8 amino acids; or polyethyleneoxy unit of formula (OCH2CH2)p or (OCH2CH(CH3))p, wherein p is an integer from 0 to about 1000; or a combination above thereof;
R11 and R12 are independently H or a linear or branched C1-C5 alkyl;
R11 is H, R14, —R14C(═O)R16, —R14C(═O)X2R16, —R14X2R16, or —R14C(═O)X2, wherein X2 is —O—, —S—, —NH—, —NHS(O2)—, —NHS(O)—, —N(R14)—, —O—R14—, —S—R14—, —S(═O)—R14—, or —NHR14—;
R1 and R2, R3 and R4, R5 and R6, or R12 and R13 may together form a 3-7 membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic or heteroaromatic ring system;
R13 is C3-C10 Ar, Ar is an aromatic or hetero aromatic group, composed of one or several rings, wherein one or several H atoms in the aromatic group can optionally be replaced independently by R17, F, Cl, Br, I, OR16, SR16, NR16R17, N═NR16, N═R16, NR16R17, NO2, SOR16R17, SO2R16, SO3R16, OSO3R16, PR16R17, POR16R17, PO2R16R17, OP(O)(OR17)2, OCH2OP(O)(OR17)2, OC(O)OP(O)(OR17)2, PO(OR16)(OR17), OP(O)(OR17)OP(O)(OR17)2, OC(O)R17 or OC(O)NHR17;
wherein R16 is H, OH, R14 or one to four amino acid units;
wherein R14, R17 and R18 are independently H, a linear or branched C1-C8 alkyl; C2-C8 alkenyl, alkynyl, heteroalkyl, or heterocyclic; C3-C8 aryl, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, or alkylcarbonyl; or C4-C12 glycoside.

### Claim 2 (depends on 1)

The conjugate according to claim 1, wherein:
R1 is a linear or branched C1-C8 alkyl;
R2 is absent;
R7 is a linear or branched C1-C8 alkyl; C2-C8 alkenyl, or C3-C8 aryl;
R9 is —OR20, wherein R20 is an acyl (—C(O)R17);
R10 and R12 are H,
R11 is —R14C(═O)X2, wherein R14 is C1-C8 alkyl, X2 is —OH;
R13 is C3-C10 Ar; or
in W, R20 is —C1-C9 alkylene-.

### Claim 3 (depends on 1)

The conjugate according to claim 1, wherein R13 is C3-C6 Ar.

### Claim 4 (depends on 1)

The conjugate according to claim 1, wherein R13 is phenyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, or pyridyl-N-oxide.

### Claim 5 (depends on 1)

The conjugate according to claim 1, wherein the structure inside the bracket of Formula (II) is a structure represented by any of following formulae:
wherein:
R7 is the same as defined in claim 1;
R21 is H; C1-C8 linear or branched alkyl, heteroalkyl, or acyl (—C(O)R17);
R21 is H, or C1-C8 linear or branched alkyl;
Z2 and Z3 are independently H, OH, NH2, OR17, NHR17, COOH, COOR17, C(O)R17, C(O)NHR17, C(O)NHNHR7, C(O)NH2, R18, OCH2OP(O)(OR18)2, OC(O)OP(O)(OR18)2, OPO(OR18)2, NHPO(OR18)2, OP(O)(OR18)OP(O)(OR18)2, OC(O)R18, OC(O)NHR18, OSO2(OR18), O—(C4-C12-glycoside), C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (—C(O)OR17), carbamate (—C(O)NR17R18);
R17 and R18 are independently H, C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate, carbamate;
“” is a site that links to a linker L.

### Claim 6

A conjugate having a structure of Formula (VII):
or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or an isotope, optical isomer, racemate, diastereomer or enantiomer thereof,
wherein:
T is an antibody;
L is a releasable linker having a formula: -Ww-(Aa)r-Vv-, wherein:
—W— is
wherein R20 is —C1-C9 alkylene-, —O—(C1-C8 alkyl)-, —(CH2CH2O)k—, or —(CH2CH2O)k—CH2—, k is an integer ranging from 1-20;
w is 0 or 1;
each -Aa- is independently an amino acid unit;
r is independently an integer ranging from 0 to 12;
V is *(CH2CH2O)n*;
wherein X2, X3 and X5 are independently NH, O, C1-C6 alkyl, alkylcarbonyl, or a combination thereof;
v is 0, 1 or 2;
n is 1-20;
m is 1-10;
the structure inside the bracket of Formula (VII) is a structure represented by any of following formulae:
wherein:
R7 is R14, —R14C(═O)X1R15 or —R14X1R15; X1 is selected from O, S, S—S, NH, or NR14;
R14 and R1s are independently H, a linear or branched C1-C8 alkyl; C2-C8 alkenyl, alkynyl, heteroalkyl, or heterocyclic; C3-C8 aryl, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, or alkylcarbonyl;
R20 is H; C1-C8 linear or branched alkyl, heteroalkyl, or acyl (—C(O)R17); C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; carbonate (—C(O)OR17), carbamate (—C(O)NR17R18); or C1-C8 carboxylate, ester, ether, or amide; or 1-8 amino acids; or polyethyleneoxy unit of formula (OCH2CH2)p or (OCH2CH(CH3))p, wherein p is an integer from 0 to about 1000; or R21 is absent and the oxygen forms a ketone, or a combination above thereof;
R21 is H, C1-C8 linear or branched alkyl;
X, X1, X2 and X3 are independently O, S, NH, NHNH, NHR17, CH2 or absent;
Pl is H, R17, P(O)(OH)2, P(O)(X1R17)2, CH2P(O)(OH)2, S(O2)(X1R17), C6H12O5(glycoside), or (CH2CH2O)pR17, wherein p is selected from 0-100;
R17 and R18 are independently H, C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; carbonate, or carbamate;
“” is a site that links to a linker L.

### Claim 7 (depends on 6)

The conjugate according to claim 6, wherein:
Aa is one or more of arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycine glutamic acid or aspartic acid;
R7 is a linear or branched C1-C8 alkyl;
R21 is C1-C8 linear or branched alkyl, an acyl (—C(O)R17) or carbamate (—C(O)NR17R18);
X1 is O;
X2 or X3 is NH; or
R21 in W is —C1-C9 alkylene-.

### Claim 8

A conjugate having one of following structures:
wherein mAb is an antibody; n is 1-20; p is 0-100.
